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Skin, the largest organ in the body, protects against toxins and microorganisms in the environment and serves
to prevent dehydration of all non-aquatic animals. Immune surveillance, sensory detection, and self-healing are
other critical functions of the skin. Loss of skin integrity because of injury or illness may result acutely in
substantial physiologic imbalance and ultimately in significant disability or even death. It is estimated that, in
1992, there were 35.2 million cases of significant skin loss (US data) that required major therapeutic
intervention. Of these, approximately 7 million wounds become chronic. Regardless of the specific advanced
wound care product, the ideal goal would be to regenerate tissues such that both the structural and functional
properties of the wounded tissue are restored to the levels before injury. The advent of tissue-engineered skin
replacements revolutionized the therapeutic potential for recalcitrant wounds and for wounds that are not
amenable to primary closure. This article will introduce the reader to the field of tissue engineering, briefly
review tissue-engineered skin replacement from a historical perspective and then review current state-of-
the-art concepts from our vantage point.
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Introduction
The problem: a failure to heal. Skin,
the largest organ in the body, protects
against toxins and microorganisms in
the environment and serves to prevent
dehydration of all non-aquatic animals.
Immune surveillance, sensory detec-
tion, and self-healing are other critical
functions of the skin. Loss of skin
integrity because of injury or illness
may result acutely in substantial physio-
logic imbalance and ultimately in
significant disability or even death. It
is estimated that, in 1992, there were
35.2 million cases of significant skin
loss (US data) that required major
therapeutic intervention (1993). Of
these, approximately seven million
wounds become chronic.
The most common single cause of
significant skin loss is thermal injury,
which accounts for approximately one
million hospital emergency visits per
year in the US (2005a). Other causes of
skin loss include trauma and chronic
ulcerations secondary to diabetes mel-
litus, pressure, and venous stasis. In a
recent fact sheet published by the
Center for Disease Control and Preven-
tion, the estimated prevalence of dia-
betes in the US population is 7% or 21
million individuals (2005b). Of these
up to 10% (2 million) have chronic
diabetic ulcers, many of which
(B82,000) eventually necessitate am-
putation (Ehrenreich and Ruszczak,
2006). According to Ehrenreich and
Ruszczak (2006), the Medicare cost for
amputations alone in this population
was $1.5 billion in 1995. Approxi-
mately 600,000 patients suffer from
venous ulcers at an average cost of
$9,685 per patient (Olin et al., 1999).
Another 1.4 million people in the US
have pressure ulcers. The total treat-
ment costs for these two group has
been estimated to be as high as $8
billion annually (Supp and Boyce,
2005). In 2003, a survey estimated the
US market for advanced wound care
products, including biological and syn-
thetic dressings, to be greater than $1.7
billion and predicted significant in-
crease as the population ages, becom-
ing more susceptible to underlying
causes of chronic wounds (2003; Grin-
nell and Lamke, 1984). The quality of
life of patients with chronic wounds
can be extremely poor, thus adding
indirect costs to the burden of cuta-
neous ulcers. Therefore, the total
cost of chronic wounds is difficult to
assess.
Over the past three decades, there
have been extraordinary advances in
our understanding of the cellular and
molecular processes involved in acute
wound healing and in the pathobiology
of chronic wounds (Singer and Clark,
1999; Mustoe, 2004; Ghosh and Clark,
2007). A brief overview of these
physiologic and pathologic processes
is presented in Figure 1. This increased
knowledge base has led to wound care
innovations that have facilitated more
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Figure 1. Tissue injury results in an acute wound healing response under normal physiologic conditions but may fail when underlying pathobiology or
microbial invasion interfere with the healing process, thereby creating a chronic wound. (Left panel) Tissue injury precipitates blood clotting, platelet
aggregation, and migration of leukocytes, including neutrophils and macrophages, to the site of injury. Initially, the blood clot is composed of fibrin and
fibronectin, which provide a scaffold for cell migration and aggregated platelets, which release growth factors into the surrounding tissue. By 3 days the clot has
synerzied (contracted) and accumulated numerous neutrophils, which phagocytose and kill microorganisms; and macrophages, which produce and secrete
growth factors into the wound environment. Although epidermal migration along the interface between the clot and surrounding normal tissue begins within
24 h after injury, no tissue cells have invaded the clot even by 3 days. Nevertheless by 3 days, fibroblasts and endothelial cells in the periwound stroma are
activated to express the appropriate integrins (ECM receptors) for migrating on fibrin and fibronectin, and to secrete growth factors. Epidermal cells also
participate in this cytokine network of growth factor release at 3 days. (Upper right panel) Under normal physiologic conditions the wound continues to heal at 5
days with an ingrowth of granulation tissue composed of fibroblasts, additional macrophages, and neovasculature. The migrating epidermis now changes its
course and migrates over the newly forming tissue. Proteases restricted to the leading edge of migrating tissue cells are critical for their invasion of the clot and
ingrowth into the wound. These proteases include urokinase type-plasminogen activator (uPA), tissue-type plasminogen activator (tPA), and matrix
metalloprotineases 1, 2, 3, 9, and 13 (MMP 1, 2, 3, 9, and 13). The latter include collagenases (MMP 1 and 13), gelatinases (MMP 2 and 9), and stromolysin
(MMP 3). Many growth factors released by platelets and secreted by macrophages during the first phase of healing have been sequestered in the
provisional matrix and stimulate tissue cells as they move into the wound. To these are added growth factors now secreted by tissue cells themselves including
epidermal cells, fibroblasts, and endothelial cells as well as macrophages. (Lower Right Panel) When underlying pathobiology or microorganism invasion
interrupts the wound healing process, a failure to heal occurs often leading to a chronic wound (ulcer). Underlying pathobiology known to interfere with acute
wound healing includes venous insufficiency that results in fluid transudation and fibrin cuffing of venules secondary to high hydrostatic pressure in the
venous system; diabetes mellitus that results in high glucose and both cell and ECM dysfunction from non-enzymatic glycation; arterial occlusion or high
external pressure that results in tissue hypoxia and cell dysfunction or death. Bacteria colonizing the wound often produce a biofilm composed of a wide variety
of polysaccharides. The biofilm protects these colonies of mixed microorganisms, as it is relatively impervious to phagocytic cells and impermeable to
antibiotics. Frustrated phagocytes release a plethora of proteases and toxic oxygen radials into the wound milieu making a bad situation worse as these agents
destroy tissue cells, extracellular matrix, and growth factors in the wound. Not surprisingly, such chronic wounds lack epidermal migration and ingrowth of
granulation tissue.
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rapid closure of ulcer and normal
wounds, better functional and more
aesthetic scars, and decreased inci-
dence of keloids. As tumor microenvir-
onments have many similarities to
wound healing (Dvorak, 1986), better
understanding of wound healing (Ash-
croft et al., 2003) has led to advances in
tumor therapy (Basu et al., 2006).
Several specific products for wound
treatment that germinated from our
increased understanding of fundamen-
tal processes underlying wound healing
have reached the market place for
second-line therapy of recalcitrant ul-
cers (Singer and Clark, 1999; Ehren-
reich and Ruszczak, 2006). These
products include recombinant growth
factor, platelet-derived growth factor-
BB (rPDGF-BB) (Regranex, Ortho-
McNeil), and several skin substitutes
(Dermagraft and TransCyte, Advanced
Tissue Sciences; Apligraf, Organogen-
esis; Integra Matrix Wound Dressings,
Integra LifeSciences Holding; OrCel,
Ortec International; AlloDerm, Life-
Cell). Most of these interventions de-
monstrate a 25% increase in closure
or healing rates in chronic wounds
(Ehrenreich and Ruszczak, 2006). Un-
fortunately, rPDGF-BB must be applied
daily forcing patients to change their
bandages daily and two companies
producing skin substitutes have under-
gone bankruptcy and reorganization.
Regardless of the specific advanced
wound care product, the ideal goal
would be to regenerate tissues
such that both the structural and
functional properties of the wounded
tissue are restored to the levels before
injury.
Embryonic wounds, in contrast to
wounds in children and adults, under-
go regeneration during the first and
second trimester and scarless repair
early in the third trimester (Redd
et al., 2004). Morphogenetic cues from
these embryonic phenotypes could be
utilized to develop engineered con-
structs capable of tissue regeneration.
In particular, as cellular response to
biological stimuli depends on the
geometry and mechanical strength of
extracellular matrix (ECM) (Engler
et al., 2006; Vogel and Sheetz, 2006),
the therapeutic success of tissue-engi-
neered constructs will depend not only
on their bioactivity but also on their
mechanical properties.
A possible solution: tissue engineering.
The advent of tissue-engineered skin
replacements revolutionized the ther-
apeutic potential for recalcitrant
wounds and for wounds that are not
amenable to primary closure. This
article will introduce the reader to the
field of tissue engineering, briefly re-
view tissue-engineered skin replace-
ment from a historical perspective,
and then review current state-of-the-
art concepts from our vantage point.
Tissue engineering integrates many
fields of science and engineering in
order to design, develop, and test tissue
replacement for traumatically lost or
disease-damaged tissue. As such, tissue
engineering relies on the expertise of
scientists and engineers from multiple
backgrounds, including, but not limited
to, molecular and cell biology, physiol-
ogy, chemistry, physics, materials
science, applied mathematics, biome-
dical engineering, mechanical engi-
neering, and chemical engineering.
These individuals work across a broad
temporal-spatial scale from nanose-
conds to years and from nanometers
to meters. Together they develop not
only the biomaterials or organotypic
assemblages for implantation but also
the manufacturing processes necessary
to synthesize biomaterials as well as
bioreactors required to grow large
quantities of genes, cells, or organoty-
pic tissue.
Two major approaches, an in vitro
and an in vivo, have been utilized to
develop engineered tissue. The in vitro
method has received the most attention
from the lay-press as it is this approach
that attempts to create organs in tissue
culture or bioreactors for implantation
and replacement of diseased or da-
maged tissue. In contrast, the in vivo
approach attempts to create an acellu-
lar biomaterial that contains clues
conductive for tissue cell recruitment
into the biomaterial and inductive of
cell differentiation to form the needed
tissue. Regardless of whether they
contain cells or not, many fabrications
engineered for implantation contain a
bioactive and a biopolymer backbone
(Figure 2). Bioactives are selected to
stimulate tissue cells to migrate and
proliferate, and ultimately to differenti-
ate. Biopolymers typically provide me-
chanical support for cell migration and
proliferation. However, when prepared
from natural ECM, these scaffolds and
hydrogels may provide additional bio-
logical stimuli to support cell and tissue
function (Lutolf and Hubbell, 2005).
Importantly, the engineered bioactive-
biopolymer construct and tissue cells,
whether preloaded or host-derived,
must interact to initiate a dynamic
reciprocity for further tissue develop-
ment (Nelson and Bissell, 2005).
Ideally, tissue-engineered skin replace-
ments should facilitate faster healing
and promote the development of a new
tissue that bears a close structural and
functional resemblance to the unin-
jured host tissue.
Historical perspective of
tissue-engineered skin replacement
Composite synthetic or biological dres-
sings are often used to speed wound
repair and improve the quality of
healing in chronic or burn wounds
(Robson et al., 1973; Gokoo and
Burhop, 1993; Purna and Babu,
2000). Although effective, these dres-
sings do not offer permanent treatment.
Eventually, a split-thickness autograft
or allograft may be required to achieve
complete healing. However, tissue
harvest and transplantation are accom-
panied by undesirable consequences
such as the risk and expense of surgery,
donor site morbidity, and rejection of
the transplanted tissue. To remedy
these problems, the goal of tissue
engineering has been to substitute
tissue-engineered skin replacements
for autografts or allografts. The first step
toward this end was to substitute split-
thickness autografts with autologous
epidermal sheets grown from small
punch biopsies.
Autologous and allogenic epidermal
replacement. Cultured autologous epi-
dermal sheets have been used to
facilitate repair of both epidermal and
partial thickness wounds. Autologous
epidermal sheets were first used to
cover burn wounds (O’Conner et al.,
1981), and burns have remained the
major clinical target for both autolo-
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gous and allogenic epidermal replace-
ment (Ehrenreich and Ruszczak, 2006).
Implantation of epidermal grafts cul-
tured from a small skin biopsy was
made possible when tissue culture
techniques were perfected to grow
epidermal cells in large quantities
(Rheinwald and Green, 1975; Green
et al., 1979). Subsequently, there has
been extensive experience with cul-
tured epidermal grafts for the treatment
of burns as well as other acute and
chronic wounds (Gallico et al., 1984;
Odessey, 1992; Munster, 1996). Bior-
eactor design, patterned after the
breakthroughs in epidermal cell tissue
culture techniques, has allowed this
technology to reach the marketplace as
EpicelTM (Genzyme Tissue Repair).
Autologous epidermal sheets serve as
permanent wound coverage as the host
does not reject them, and yield a
reasonable cosmetic result. Disadvant-
ages do exist and include the 2–3 week
time interval required before sufficient
quantities of keratinocytes become
available and the large costs estimated
at $13,000 per 1% total body surface
area covered (Rue et al., 1993).
Furthermore, graft-take can vary widely
secondary to wound preparation and its
intrinsic status, patient underlying dis-
ease, and operator experience.
Cultured epidermal sheet allografts
were developed to overcome the ne-
cessity to biopsy each patient and then
wait 2 to 3 weeks between epidermal
harvest and autograft product. With the
utilization of techniques for culturing
epidermal sheets, epidermal cells from
both cadavers and unrelated adult
donors have been used for the treat-
ment of burns (Madden et al., 1986),
donor sites of skin grafts (Thivolet et al.,
1986), and chronic leg ulcers (Leigh
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Figure 2. The basic building blocks of a tissue-engineered construct are a biopolymer, one or more biomimetics, and perhaps cells. The biopolymer must be
biocompatible and biodegradable. Biomimetics are selected to add function to the biopolymer. The bioactive function may be cell-binding activity, growth
factor activity, or growth factor-binding activity, or enzymatic activity or enzyme-binding activity. Cells added exogenously to the engineered biopolymer may
be used to induce a functioning tissue-substitute for transplantation (left schemata). These cells may be stem cells or genetically engineered cells. When an
acellular biopolymer is implanted, enough information must be available within the engineered construct to support endogenous tissue cell ingrowth and
appropriate differentiation for tissue formation (right schemata).
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et al., 1987). The source for most
current allografts is neonatal foreskin
keratinocytes, which are more respon-
sive to mitogens than adult (cadaver)
cells (Phillips, 1998). Such allografts
promote accelerated healing and effect
pain relief in a variety of acute and
chronic skin ulcers without any evi-
dence of immunological rejection;
however, the keratinocytes within
these allografts are replaced within a
few weeks by ingrowth of recipient
cells. To facilitate mass allograft pro-
duction and wide availability, cryopre-
served allografts were developed.
These frozen constructs gave compar-
able results to fresh allografts (Teepe
et al., 1990; De Luca et al., 1992).
Although cultured epidermal auto-
graphs and allografts can be used
successfully to cover partial thickness
burns, they fail to produce a satisfac-
tory response in deeper burns and other
full-thickness wounds (Williamson
et al., 1995). The primary reasons
include lack of mechanical strength
and susceptibility to contractures. As
an alternative, keratinocyte delivery
systems were developed by which cells
are delivered to the injury site via a
biodegradable scaffold. For example,
Laserskin, produced by FIDIA Ad-
vanced Biopolymer, Italy, is used to
deliver keratinocytes via a chemically
modified hyaluronan membrane (Cam-
poccia et al., 1998), perforated with
micron-sized holes that allow cells to
grow to confluence. Alternatively ker-
atinocytes can be delivered to wounds
intermixed with fibrin sealant as a spray
(Grant et al., 2002). However, this may
not prove to be an optimal delivery
system as keratinocytes lack receptors
for fibrin or fibrinogen (Kubo et al.,
2001).
Engineered Dermal Constructs. While
cultured epidermal sheets do enhance
healing, especially of burn wounds,
they lack a dermal component that, if
present, might prevent wound contrac-
tion and provide greater mechanical
stability. Cadaver skin allografts con-
taining both epidermis and dermis have
been used for many years, but provide
only temporary coverage because of
host rejection. However, allografts can
be chemically treated to remove
immunogenic cellular elements, for ex-
ample, Alloderm (Life Cell Corporation,
Woodlands, TX). Such ‘‘decellulari-
zed’’ allografts have been effectively
used alone or in combination with
cultured autologous keratinocytes for
closure of burns and chronic wounds
(Cuono et al., 1986).
In 1981, a composite of bovine
collagen and chondroitin-6-sulfate
from shark cartilage, with an outer
silicone covering, was engineered as
an organotypic dermis for skin grafting
(Burke et al., 1981). After wound
placement, the acellular composite
recruited host dermal fibroblasts and
was degraded during cell invasion. The
silicone sheet was removed 2–3 weeks
after placement, and the wound cove-
red with an epidermal sheet autograft.
This organotypic dermis material has
been successful in treating burns
(Heimbach et al., 1988) and has
received FDA approval for this indica-
tion (Integra, LifeSciences Corporation,
Plainsboro, NJ). This material, how-
ever, must be avoided in patients who
have developed allergic reactions to
bovine products.
Another acellular implant called
Transcyte (Dermagraft-TC) was pro-
duced by Advanced Tissue Sciences
Inc. (ATS, La Jolla, CA). This composite
consisted of an inner nylon mesh in
which human foreskin fibroblasts were
embedded and an outer silicone layer
to limit evaporation. Fibroblasts were
allowed to synthesize and secrete ECM
material, such as collagen, fibronectin,
and glycosaminoglycans; and cyto-
kines, including growth factors. After
a few weeks the cells were disrupted by
freeze–thawing to create the final pro-
duct. Transcyte was successful as a
temporary wound coverage after exci-
sion of the eschar from burn wounds
(Purdue, 1997) and approved by the
FDA for this indication. ATS also
produced a cellular composite, called
Dermagraft. In this construct, human
foreskin fibroblasts were cultured in a
biodegradable polyglactin mesh and
then cryo-preserved so that they re-
mained viable. Dermagraft had limited
success in the treatment of diabetic foot
ulcers (Gentzkow et al., 1996). As
Dermagraft did not appear to stimulate
immune rejection, it was first viewed as
a dermal substitute (Marston et al.,
2003). However, the human foreskin
fibroblasts implanted with this material
die within a few weeks after implanta-
tion; therefore, the product more likely
acts as a delivery vehicle for growth
factors and ECM produced by the
fibroblasts while they were extant
(Ehrenreich and Ruszczak, 2006). Un-
fortunately, ATS filed for bankruptcy in
2002 (Bouchle, 2002) was acquired by
Smith and Nephew and then was
closed. Although Transcyte and Der-
magraft are currently off the market,
these technologies have been licensed
to Advanced BioHealing for further
production and marketing. Problems
with these products that attributed to
their demise included difficulties in
quality control and expense (Ehren-
reich and Ruszczak, 2006). In addition,
Dermagraft was demanding to store
and complex to use. Furthermore,
reports on the clinical use of Derma-
graft are relatively scarce compared to
other dermal-like composites such as
Alloderm and Integra (Ehrenreich and
Ruszczak, 2006).
Porcine small intestinal submucosa
acellular collagen matrix (Oasis, Cook
Biotech Inc., West Lafayette, IN) and an
acellular xenogeneic collagen matrix
(E-Z-Derm) are also available and have
relatively long shelf lives. A recent
randomized clinical trial with small
intestinal submucosa in 120 patients
with venous leg ulcers demonstrated
significantly increased healing at 12
weeks (55 versus 34%) in patients
receiving small intestinal submucosa
dressing weekly plus compression ver-
sus patients receiving compression
alone (Mostow et al., 2005). Although
swines appear relatively resistant to
prion disease (Wells et al., 2003),
possibly secondary to more inherent
structural stability of their prion protein
(PrPC) (Lysek et al., 2005), prion
disease and porcine retroviruses are a
concern that needs to be addressed in
xenograft products (Alisky, 2004).
Engineered skin substitutes. Full thick-
ness wounds involve the loss of skin
epidermis and dermis. To treat wounds
of this depth, a bilayered composite
composed of a contracted collagen
lattice containing dermal fibroblasts
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(Bell et al., 1979) and an overlying
epidermal sheet was designed (Bell
et al., 1981). Subsequently, a modifica-
tion of this organotypic skin substitute
utilizing type I bovine collagen and live
allogeneic human neonatal foreskin
fibroblasts and keratinocytes was de-
veloped (Apligraf, Organogenesis, Can-
ton, MA) and marketed (Norvartis,
Zurich, Switzerland). It provided bene-
fit in surgical wounds (Eaglstein et al.,
1995) and venous ulcers (Sabolinski
et al., 1996) and is FDA approved for
the latter. In a large multicenter trial
this product resulted in approximately
25% accelerated healing of chronic
non-healing venous stasis ulcers when
compared to standard compressive
therapy (Falanga et al., 1998). Signs of
wound infection, however, were ob-
served in 29% of patients receiving
Apligraf versus 14% in patients receiv-
ing standard of care. Apligraf does not
result in immunologic rejection (Eagls-
tein et al., 1999); however, donor cells
do not remain viable beyond 4–8
weeks. Although Apligraf was first
marketed as an organotypic skin sub-
stitute, the lack of long-term viable
cells counters this claim. It is now
believed that Apligraf works by deliver-
ing growth factors and ECM to the
wound bed (Ehrenreich and Ruszczak,
2006). The product is provided in a
75-mm tissue culture dish and has a
shelf life of 5–10 days. Thus, shipping
must be closely coordinated with the
patient’s clinic visit. Apligraf costs
approximately $30 per square cm,
because this product like Dermagraft
has a high cost to produce, maintain
and transport (Bouchle, 2002). Orga-
nogenesis filed for bankruptcy in 2002
after being unable to provide these
complex organotypic constructs at the
marketed wholesale cost (Bouchle,
2002). After undergoing reorganiza-
tion, Organogenesis is now back in
business selling Apligraf, as well as
other advanced wound care products.
Several other composite skin sub-
stitutes combining dermal and epider-
mal elements have been developed.
A composite cultured skin substitute
(OrCel, Ortec International Inc., New
York, NY) is composed of both neona-
tal keratinocytes and fibroblasts em-
bedded on opposite sides of bilayered
bovine type I collagen. This product is
currently being evaluated in clinical
trials for the treatment of burns, in
patients with epidermolysis bullosa and
in split-thickness donor sites (Still et al.,
2003).
More extensive comparative data of
the various tissue-engineered biologic
dressings has been published else-
where (Ehrenreich and Ruszczak,
2006).
Tissue-engineered skin replacement:
state-of-the-art
Although increased healing rates of
burn and/or chronic wounds can be
observed with current engineered con-
structs, several intrinsic shortcomings
limit their use: (a) epidermal grafts are
fragile and therefore difficult to handle;
(b) cell-populated matrices used in
‘‘skin substitutes’’ are not readily scal-
able for manufacturing and are difficult
to store and transport; (c) autografts
require creation of fresh wounds; (d)
allografts or xenografts may induce
immune rejection; and (e) skin substi-
tutes, allografts, or xenografts may
carry infectious agents including prions
(Nunery, 2001). In part because of the
latter possibility, it has been recently
recommended that informed consent
be obtained from all patients before the
implantation of such biological materi-
al (Enoch et al., 2005). Moreover, skin
substitutes promote the healing of
chronic leg ulcers only about 25% over
patients receiving standard of care
(Falanga et al., 1998). These limitations
suggest that further improvements are
needed to insure that tissue-engineered
constructs are less complex, more cost
effective and user friendly, and carry
minimal risk of infection.
To develop acellular, cost effective,
user-friendly constructs based on non-
animal products, cues should be taken
from embryogenesis, morphogenesis,
and the acute wound healing process
(Lutolf and Hubbell, 2005). As tissue
cells themselves are the primary source
of various ECM molecules that facilitate
and synchronize tissue repair, any
acellular product must, therefore, be
conductive to rapidly recruit host tissue
cells and inductive to stimulate invad-
ing cells to proliferate, synthesize new
ECM, and, if required, differentiate. The
continuum of cell–ECM interactions
over time is essential for tissue forma-
tion and has been called dynamic
reciprocity (Nelson and Bissell, 2005).
Although synthetic and natural bio-
polymers have both been used experi-
mentally to design tissue-engineered
constructs for skin wounds and other
uses (Lutolf and Hubbell, 2005), tissue-
engineered products on the market for
skin wounds have almost exclusively
been based on natural, mostly animal-
derived, biopolymers (Ehrenreich and
Ruszczak, 2006). The reasons for this
include biocompatibility, intrinsic cel-
lular signals, and appropriate mechan-
ical properties. Nevertheless,
mechanical properties of synthetic bio-
polymers can be rigorously controlled.
Therefore, such materials have been
used in vitro to demonstrate the funda-
mental effects of viscoelastic properties
on animal cells (Discher et al., 2005)
and human mesenchymal stem cells
from bone marrow (Engler et al., 2006).
Recently, the authors have developed a
system in which the biopolymer and
bioactive are derivative of human
materials, which are synthesized in
genetically engineered bacteria, and
whose viscoelastic and biomimetic
properties can be independently and
rigorously controlled (Ghosh et al.,
2006b). Using these ‘‘natural’’ building
blocks for tissue engineering, we have
begun to perform in vitro studies on
human adult cell adaptation to varia-
tions of ‘‘natural’’ biomimetics and
biopolymers (Ghosh et al., 2006a), as
well as in vivo testing in animal
wound-healing models (Ghosh et al.,
2006b).
For the past several decades, many
engineered skin constructs have uti-
lized collagen as a scaffolding material
for cell seeding (Balasubramani et al.,
2001). Collagen’s popularity can be
attributed to its abundance in skin, its
recognition by cell surface receptors,
and its ability to crosslink and thereby
impart appropriate mechanical strength
to the tissue (Ruszczak, 2003). Col-
lagen, however, appears during the
later stages of wound healing after
fibroblasts have invaded and filled the
wound space (Welch et al., 1990).
Thus, a scaffold constructed mainly of
collagen may not be optimal for tissue
www.jidonline.org 1023
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cell migration. In the acute wound-
healing response, fibroblasts migrate
into a fibrin/fibronectin-rich clot and
then synthesize and secrete hyaluronan
and fibronectin as a second provisional
matrix that in turn promotes even more
robust migration (Ghosh and Clark,
2007). Hyaluronan also appears coin-
cident with tissue cell migration during
embryogenesis and morphogenesis
(Toole et al., 2005).
Hyaluronan, a non-sulfated glycosa-
minoglycan, especially prominent in
umbilical cord, vitreous humor, and
articular cartilage, occurs in abun-
dance in the normal adult epidermis
and dermis (Sakai et al., 2000; Bour-
guignon et al., 2006). During wound
repair, it serves multiple important
functions, ranging from regulating in-
flammation to promoting fibroblast
migration and proliferation (Chen and
Abatangelo, 1999). Importantly, hya-
luronan has been implicated in the
regeneration and scarless healing of
fetal wounds, perhaps owing to its
ability to modulate inflammation (Wis-
niewski and Vilcek, 1997) and collagen
deposition (Longaker et al., 1991).
Similar to synthetic polymers, hyalur-
onan can be chemically modified to
create a variety of stable derivatives
(Prestwich et al., 1998). An additional
advantage of hyaluronan is the
capability to engineer its synthesis in
bacteria, thereby avoiding the need to
extract it from animals (Hoshi et al.,
2004). By offering the advantages of
both natural and synthetic materials,
hyaluronan may be close to an ideal
biopolymer for tissue engineering. In-
deed, chemically modified hyaluronan
scaffolds have been successfully used
for various tissue engineering applica-
tions, including wound repair (Cam-
poccia et al., 1998; Kirker et al., 2002;
Ghosh et al., 2006b). With particular
importance to wound repair, chemi-
cally modified hyaluronan can be
intermolecularly crosslinked to impart
increased resistance to hyaluronidase
Native HA Thiol-derivatized HA X-linked HA (xHA)
PDGF-preloaded scaffold
Biomimetic tethered
to xHA
Alterations in
Biochemical 
stimuli from
biomimetics
Mechanical 
stimuli from 
xHA viscoelastic
properties
No PDGF
Scaffold Scaffold + PDGF
PDGF in media PDGF
pre-loaded
HA backbone
PEGDA X-linker
Biomimetic (RGD or 
FN domains; C, H, HV)
Thiol groups
PDGF
16 µm
500 µm
xHA-C, H, HV
95 Pa 4270 Pa
95 Pa 4270 Pa
xHA-RGD
Figure 3. Example of an acellular, functionalized, tissue-engineered biopolymer for acceleration of cutaneous wound healing. Thiol-derivatized Hyaluronan
(HA-DTPH) was synthesized as previously described (Shu et al., 2002). Homobifunctional poly(ethylene)glycol (PEG) derivatives were added to HA-DTPH to
intermolecularly crosslink hyaluronan (xHA) and also to tether cys-tagged fibronectin functional domains (C, H, HV) to the xHA (Biomimetic tethered to xHa)
(Ghosh et al., 2006b). Biochemical stimuli from biomimetics: xHA tethered with C, H, and HV was fully permissive for healing of reinjured porcine cutaneous
wounds while xHA tethered with RGD peptides inhibited healing. Mechanical stimuli from xHA viscoelastic properties: Less stiff xHA (95 Pascals) failed to
support full spreading of cultured fibroblasts, which showed buckling of actin bundles, while stiffer xHA (4270 Pa) supported robust spreading of fibroblasts,
which showed tense actin bundles. Less stiff xHA tethered with C, H, and HV (95 Pa) did not enhance healing 4-day wounds while stiffer constructs (4270 Pa)
increased granulation tissue formation by 75% at 4 days. When PDGF was preloaded in the stiffer xHA constructs tethered with C, H, HV (PDGF-preloaded
scaffold), the healing of 4-day wounds was further increased to almost double the normal healing rate as judged by re-epithelialization, granulation tissue
formation, and angiogenesis. In addition, xHA tethered with C, H, and HV and preloaded with PDGF promoted fibroblast migration in vitro to the same extent as
PDGF in solution.
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digestion and to create a hydrogel with
viscoelastic properties intermediate be-
tween a fibrin clot and normal dermis
(Ghosh et al., 2005, 2006b).
Our laboratory used the morphoge-
netic clues outlined in the preceding
paragraph to select hyaluronan as a
platform for the design, creation, and
testing of crosslinked biopolymers teth-
ered with bioactives to enhance acute
or chronic cutaneous wounds (Fig-
ure 3). As an example of a rationally
designed material to facilitate restora-
tion or replacement of injured or lost
tissue, we will take the reader through
the steps of this process. As fibroblast
migration is the rate-limiting step in
granulation tissue formation (McClain
et al., 1996), a bioactive was sought
that optimally supports migration of
activated fibroblasts. Fibronectin was a
favorable candidate for this role as (a) it
appears together with hyaluronan at
times of cell migration during embry-
ogenesis, morphogenesis, and wound
repair (Ghosh and Clark, 2007); (b)
fibroblasts invade hyaluronan/fibronec-
tin gels approximately four-fold better
than fibrin/fibronectin gels (Greiling
and Clark, unpublished observation);
(c) fibronectin is required for fibroblast
transmigration from a collagen to fibrin
matrix (Greiling and Clark, 1997); and
(d) fibronectin is absent in chronic
wounds (Herrick et al., 1992), where
it is produced normally (Herrick et al.,
1996) but eliminated rapidly by abun-
dant proteases (Grinnell et al., 1992;
Grinnell and Zhu, 1996). Although
fibronectin appears to be an ideal
bioactive for use in hyaluronan gels,
its stability in the proteolytic environ-
ment of chronic wounds is a major
concern.
An alternative biomimetic for use in
engineered wound healing materials is
arginine–glycine–asparatic acid (RGD),
a proteolytically stable peptide se-
quence from the 10th fibronectin type
III repeat that supports mesenchymal
cell attachment to surfaces (Pierschba-
cher and Ruoslahti, 1984). The RGD
sequence, also present in a variety of
other ECM molecules, is recognized by
transmembrane integrin receptors of
multiple cell types, including dermal
and epidermal tissue cells (Pfaff, 1997).
In fact, RGD has been widely used to
promote cell attachment and spreading
in various tissue engineering applica-
tions, in general (Hersel et al., 2003),
and wound healing applications in
particular (Pierschbacher et al., 1994).
Previously, we observed that a bioma-
terial consisting of RGDS (arg–gly–asp–-
ser) peptides tethered to hyaluronan
hydrogels supports NIH 3T3 fibroblast
functions in vitro (Shu et al., 2004) and,
when seeded with 3T3 fibroblasts and
implanted in nude mice, produces
granulation-like tissue in 4 weeks.
Although RGD-modified hyaluronan
hydrogels possessed great inductive
properties for mouse 3T3 cells, they
did not support human adult dermal
fibroblast functions nor demonstrate
the conductive properties (ability to
support fibroblast growth into the
wound) required of an acellular scaf-
fold in porcine wounds (Ghosh et al.,
2006b).
To create an acellular matrix with
both inductive and conductive proper-
ties, three fibronectin functional do-
mains, FNIII(811), FNIII(1215), and
FNIII(12V15), were selected as the
bioactive As they are required for
optimal human adult dermal fibroblast
migration in both two-dimensional and
three-dimensional systems in vitro
(Clark et al., 2003). When hyaluronan
hydrogels were tethered with the three
fibronectin functional domains, the
resulting construct supported human
adult dermal fibroblast functions in
vitro and promoted wound healing in
vivo (Ghosh et al., 2006b). The cross-
linked hyaluronan hydrogel possesses
several positive characteristics. as it is
formulated at room temperature and
physiological pH, cells or additional
bioactives can be incorporated in the
construct without denaturation. Rapid
curing (o10 min) allows in situ gela-
tion after tissue injection by any route.
The hydrogel’s viscoelastic properties
lie in the range between a fibrin clot
and normal human dermis. Likewise,
the bioactive fibronectin domains have
several positive attributes. They are
based on human plasma fibronectin
and thus immunocompatible. They can
be expressed in bacteria without loss of
function as post-translational modifica-
tion is not necessary for fibronectin
function. Therefore, their production is
cost-effective and carries minimal risks
of viral or prion infection. Importantly,
the hyaluronan–fibronectin domain-
engineered biopolymer can be formu-
lated into multiple physical forms
including hydrogels that can be pre-
formed or formed in situ, lyophilized
scaffolds, and electrospun nanofibrous
networks (Ji et al., 2006) that may
more closely mimic natural ECM
architecture.
With similar objectives, several
other groups have also developed
‘‘intelligent’’ scaffolds for tissue repair
(Rosso et al., 2005). Their approaches
commonly employed synthetic materi-
als to build scaffolds that allowed great
flexibility during formulation. To im-
part bioactivity, these scaffolds contain
biomimetics that can be recognized by
tissue cells. One potential advantage of
natural-derived materials over synthetic
materials is that degradation of natural
ECM can occur concomitant with cell
invasion as it does normally during
granulation tissue formation. To elicit a
similar response in synthetic materials,
protease-sensitive sequences can be
incorporated within the scaffold that
are cleaved upon contact with cell-
secreted proteolytic enzymes (Gobin
and West, 2002; Lutolf et al., 2003).
Traditionally, biopolymers were
thought to provide passive mechanical
support to tissue-engineered compo-
sites. This view arose from the belief
that cells respond to biological, rather
than mechanical, signals. However,
reports over the past few years demon-
strate that mechanical forces can also
govern cell and tissue phenotype
(Huang and Ingber, 1999; Geiger
et al., 2001; Riveline et al., 2001;
Ingber, 2003). In fact, cells use an
active tactile sensing mechanism to feel
and respond to substrate mechanics (Lo
et al., 2000; Discher et al., 2005; Vogel
and Sheetz, 2006). Importantly, dermal
fibroblast response to substrate me-
chanics includes alteration in gene
expression that can eventually lead to
differential ECM synthesis or their
phenotypic transformation into myofi-
broblasts (Chiquet et al., 2003; Hinz,
2006). Furthermore, circulating human
bone marrow-derived mesenchymal
stem cells, which can populate and
enhance cutaneous wound healing
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(Badiavas et al., 2003; Chapel et al.,
2003), are exquisitely sensitive to ECM
mechanical properties, leading to dif-
ferent differentiated phenotypes de-
pending on matrix stiffness (Engler
et al., 2006). As these processes are
critical during wound healing, tissue
engineering approaches for wound
repair would require optimization
of both biological and mechanical
effectors.
Acellular tissue-engineered con-
structs discussed thus far utilize biopo-
lymers to provide mechanical support
for tissue ingrowth, and biomimetics to
induce key cell functions. The primary
goal of this approach is to mimic the
attributes of the wound provisional
matrix that is conductive for parench-
ymal cell migration and inductive of
the appropriate differentiation for new
tissue formation. However, a fibrin clot
is not only composed of a fibrin/
fibronectin scaffold and an array of
clotting and fibrinolytic enzymes, but
also of multiple growth factors that had
been released during platelet aggrega-
tion (Mosesson, 2005). Growth factors
play a crucial role in the healing
response where they function to stimu-
late cell migration, proliferation, and
differentiation. Growth factor defi-
ciency often leads to impaired healing
(Crowe et al., 2000; Peters et al., 2005).
As a result, several groups have inves-
tigated the use of tissue-engineered
constructs for local growth factor de-
livery (Richardson et al., 2001; Cai
et al., 2005).
It is important to note that in spite of
growth factor release from platelets and
injured cells immediately after wound-
ing, a 3-day lag time occurs before
granulation tissue begins (McClain
et al., 1996). This fact suggests that
growth factors may bind the clot and
retain functional activity. Such ‘solid-
state’ chemical biology is supported by
data that basic fibroblast growth factor
and vascular endothelial growth factor
bind to fibrin and retain their biological
activity (Sahni and Francis, 2000; Sahni
et al., 2004) and that IGF and vascular
endothelial growth factor bind to fibro-
nectin and retain their bioactivity (Gui
and Murphy, 2001; Wijelath et al.,
2002). Furthermore, studies from our
laboratory have shown that PDGF,
when preloaded onto hyaluronan hy-
drogels containing specific domains of
fibronectin, retains its activity at a level
typically observed with a much higher
concentration in solution (Ghosh and
Clark, unpublished observations).
Although the finding was counterintui-
tive from the vantage of glycosamino-
glycans, since heparin, rather than
hyaluronan, has been demonstrated to
bind a variety of growth factors (Klags-
brun, 1990; Shirakata et al., 2005), it is
consonant with the ability of fibronec-
tin to bind other growth factors. Re-
gardless of the mechanism employed,
by incorporating appropriate growth
factor-binding materials, a tissue-engi-
neered composite can be used as a
growth factor repository, which accent-
uates cell functions through the bioac-
tivity of bound or released growth
factors as well as for mechanical
properties attributable to the biopoly-
mer backbone and for conductive and
inductive activity attributable to other
tethered biomimetics (Figure 3).
Conclusion
Wound healing is an integrated biolo-
gical response consisting of a dynamic
reciprocity among cells, ECM and
growth factors that reconstitutes tissue
after injury. Vigorous cellular activities
observed during wound repair are
similar to those occurring during em-
bryogenesis and morphogenesis indi-
cating the enormous complexity of this
physiological reparative process. That
complexity may also explain why,
despite over two decades of intense
research and development, medical
research has still not identified an
‘‘ideal’’ therapy. However, a better
appreciation of how viscoelastic and
geometric properties of natural and
synthetic biopolymers effect cell func-
tion and multicellular organization,
how external biochemical signals inter-
face with the cell membrane in context
of the pericellular matrix, and how
signals from these physicochemical
events are transduced by a solid-state,
yet dynamic and integrative, organiza-
tion of signal transduction proteins in
the cytoplasm, is beginning to open
new horizons, which should ultimately
translate into novel ‘‘break-through’’
wound healing therapeutics.
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